Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer

Author:

Kovalchik Stephanie A.1,Ronckers Cécile M.1,Veiga Lene H.S.1,Sigurdson Alice J.1,Inskip Peter D.1,de Vathaire Florent1,Sklar Charles A.1,Donaldson Sarah S.1,Anderson Harald1,Bhatti Parveen1,Hammond Sue1,Leisenring Wendy M.1,Mertens Ann C.1,Smith Susan A.1,Stovall Marilyn1,Tucker Margaret A.1,Weathers Rita E.1,Robison Leslie L.1,Pfeiffer Ruth M.1

Affiliation:

1. Stephanie A. Kovalchik, Alice J. Sigurdson, Peter D. Inskip, Margaret A. Tucker, and Ruth M. Pfeiffer, National Cancer Institute, National Institutes of Health, Rockville, MD; Cécile M. Ronckers, Dutch Childhood Oncology Group, Late Effects After Childhood Cancer Treatment, The Hague, the Netherlands; Lene H.S. Veiga, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil; Florent de Vathaire, National Institute of Health and Medical Research, U1018, Villejuif, France; Charles A. Sklar, Memorial...

Abstract

Purpose We developed three absolute risk models for second primary thyroid cancer to assist with long-term clinical monitoring of childhood cancer survivors. Patients and Methods We used data from the Childhood Cancer Survivor Study (CCSS) and two nested case-control studies (Nordic CCSS; Late Effects Study Group). Model M1 included self-reported risk factors, model M2 added basic radiation and chemotherapy treatment information abstracted from medical records, and model M3 refined M2 by incorporating reconstructed radiation absorbed dose to the thyroid. All models were validated in an independent cohort of French childhood cancer survivors. Results M1 included birth year, initial cancer type, age at diagnosis, sex, and past thyroid nodule diagnosis. M2 added radiation (yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no). Past thyroid nodule was consistently the strongest risk factor (M1 relative risk [RR], 10.8; M2 RR, 6.8; M3 RR, 8.2). In the validation cohort, 20-year absolute risk predictions for second primary thyroid cancer ranged from 0.04% to 7.4% for M2. Expected events agreed well with observed events for each model, indicating good calibration. All models had good discriminatory ability (M1 area under the receiver operating characteristics curve [AUC], 0.71; 95% CI, 0.64 to 0.77; M2 AUC, 0.80; 95% CI, 0.73 to 0.86; M3 AUC, 0.75; 95% CI, 0.69 to 0.82). Conclusion We developed and validated three absolute risk models for second primary thyroid cancer. Model M2, with basic prior treatment information, could be useful for monitoring thyroid cancer risk in childhood cancer survivors.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3